Identity
- Trade Name
- BÜHLMANN ACE Kinetic FDA UDI
- Generic Name
- Angiotensin converting enzyme (ACE) IVD, kit, spectrophotometry FDA UDI
- Device Name
- The BÜHLMANN ACE kinetic assay is intended for the direct and quantitative in vitro diagnostic determination of angiotensin converting enzyme (ACE) activity in serum samples by enzymatic assay. FDA UDI
- Model / Reference
- KK-ACK2 FDA UDI
- Description
- The BÜHLMANN ACE kinetic assay is intended for the direct and quantitative in vitro diagnostic determination of angiotensin converting enzyme (ACE) activity in serum samples by enzymatic assay. FDA UDI
Identifiers
- Catalog Number
- KK-ACK2 FDA UDI
- Primary DI / UDI-DI
- EBUHKKACK20 FDA UDI
- FDA Product Code
- KQN FDA UDI
- GMDN Term
- Angiotensin converting enzyme (ACE) IVD, kit, spectrophotometry FDA UDI
Classification
- Device Class
- Class II FDA UDI
- Regulation Number
- 862.1090 FDA UDI
- Commercial Distribution
- In Commercial Distribution FDA UDI
Clinical & Handling
Sterile
No
FDA UDI
Single Use
No
FDA UDI
Implantable
No
FDA UDI
Contains Latex
No
FDA UDI
Prescription Use
Yes
FDA UDI
Over-the-Counter
No
FDA UDI
Convenience Kit
Yes
FDA UDI
Combination Product
No
FDA UDI
HCT/P
No
FDA UDI
Premarket Exempt
Yes
FDA UDI
Lot / Batch Number
Yes
FDA UDI
Serial Number
No
FDA UDI
Expiration Date
Yes
FDA UDI
Manufacturing Date
No
FDA UDI
Category: Angiotensin converting enzyme (ACE) IVD, kit, spectrophotometry
BÜHLMANN ACE Kinetic by Bühlmann Laboratories AG — Class II — FDA UDI — listed in FDA GUDID — regulatory data on deviCERTS
Authorization Coverage (1 country)
Regulatory Authorizations
United States Pending data
FDA UDI
| Source | Region | Type | Cert / Approval No. | Class | Status |
|---|---|---|---|---|---|
| FDA UDI | United States | FDA UDI | Registered in GUDID | Class II | Pending data |
Is this your device? Claim it to add documentation and request validation.
Manufacturer
- Manufacturer
- Bühlmann Laboratories AG
Sources (1)
- FDA UDI 66666c88-5853-4ad2-82be-c39457b5d780 35 fields · synced May 30, 2026